Miscellaneous

 | Source: Novo Nordisk A/S Novo Nordisk A/S

In accordance with Section 17(2) of the Danish Statutory Order on Issuers' Disclosure Obligations, Novo Nordisk is required on 1 June 2007 to publish the total number of voting rights and the size of the share capital in Novo Nordisk A/S.
 
Please find below a statement regarding the total number of voting rights and size of share capital in Novo Nordisk A/S as of 1 June 2007.
 
 
Number of shares (nominal value DKK 2)
Nominal value (DKK)
Number of votes
A shares
53,743,600
107,487,200
1,074,872,000
B shares
283,216,400
566,432,800
566,432,800
 
Novo Nordisk is a healthcare company and a world leader in diabetes care. The company has the broadest diabetes product portfolio in the industry, including the most advanced products within the area of insulin delivery systems. In addition, Novo Nordisk has a leading position within areas such as haemostasis management, growth hormone therapy and hormone replacement therapy. Novo Nordisk manufactures and markets pharmaceutical products and services that make a significant difference to patients, the medical profession and society. With headquarters in Denmark, Novo Nordisk employs more than 23,600 employees in 79 countries, and markets its products in 179 countries. Novo Nordisk's B shares are listed on the stock exchanges in Copenhagen and London. Its ADRs are listed on the New York Stock Exchange under the symbol 'NVO'. For more information, visit novonordisk.com.
 
For further information please contact:
 
Stock Exchange Announcement no 15/2007 
GlobeNewswire